GSK and Merck KGaA, Darmstadt, Germany announce global alliance to jointly develop and commercialise M7824, a novel immunotherapy with potential in multiple difficult-to-treat cancers
- Eight high priority immuno-oncology clinical development studies ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers
- Merck KGaA, Darmstadt, Germany will receive an upfront payment of ?300 million (?260 million) and is eligible for potential development milestone payments of up to ?500 million (?440 million) triggered by data from the M7824 lung cancer programme, plus future approval and commercial milestones of up to ?2.9 billion (?2.5 billion), for a total potential deal value of up to ?3.7 billion (?3.2 billion)